US EditionCANSON CAPITAL PARTNERS ACTS AS LEAD FINANCIAL ADVISOR TO CAPVEST ON ITS ACQUISITION OF STADA AND CO-INVESTS VIA ITS MERCHANT BANKING ARM
CapVest Partners is acquiring a majority stake in German drugmaker Stada Arzneimittel in a €10 billion deal, with Bain Capital and Cinven retaining minority stakes.
- On September 1, 2025, CapVest Partners reached an agreement to purchase controlling interest in German pharmaceutical company Stada Arzneimittel AG from Bain Capital and Cinven.
- The deal follows Bain and Cinven's 2017 acquisition and Stada's 2023 spinoff of its Russia business, with the transaction valued at about €10 billion.
- Stada is a pan-European pharmaceutical leader with over 25,000 products, generating more than €4 billion revenue in 2024 and growing adjusted earnings by 11%.
- CapVest was advised financially by Canson and Centerview, with Canson emphasizing CapVest’s two decades of experience in healthcare investments.
- The deal marks one of Europe's largest healthcare transactions this year, with Bain and Cinven retaining minority stakes and closing expected in early 2026.
51 Articles
51 Articles
CANSON CAPITAL PARTNERS ACTS AS LEAD FINANCIAL ADVISOR TO CAPVEST ON ITS ACQUISITION OF STADA AND CO-INVESTS VIA ITS MERCHANT BANKING ARM
STADA marks the sixth private equity transaction where Canson is financial advisor and co-investor LONDON, Sept. 1, 2025 /PRNewswire/ -- Canson Capital Partners ("Canson") is delighted to announce that it has acted as Lead Financial Advisor to CapVest Partners LLP ("CapVest"), a leading international private equity investor, on its agreement to invest in STADA Arzneimittel AG ("STADA"). The transaction involves the acquisition of a majority stak…
Actually, Stada wanted to return to the stock market this year, but the owners of the drug manufacturer are now surprisingly taking a different path.
Just last week, the Stada CEO had announced an IPO, but it is now clear that British financial investor CapVest will take over the majority stake in the pharmaceutical manufacturer.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
